【ChiCTR1900028604】Clinical Observation of Combined Acupuncture Points with Deep Puncture at the Acupoint Jingming BL1 for Glaucoma Treatment
ChiCTR1900028604
尚未开始
/
/
/
2019-12-28
/
/
青光眼
Clinical Observation of Combined Acupuncture Points with Deep Puncture at the Acupoint Jingming BL1 for Glaucoma Treatment
Clinical Observation of Combined Acupuncture Points with Deep Puncture at the Acupoint Jingming BL1 for Glaucoma Treatment
47100
1. To assess the effectiveness of deep puncture treatment in lowering the IOP in POAG patients. 2. To assess the effectiveness of deep puncture treatment in improving visual acuity in POAG patients. 3. To assess the safety of deep puncture at acupoint Jingming BL1 reaching a depth of 40mm from an angle of 85 degree.
单臂
回顾性研究
Selection of participants is done according to inclusion and exclusion criteria by principal investigator.
No
Self-funded
/
25
/
2020-02-03
2020-06-30
/
Study participants will be those who are: 1. of either gender; 2. > 18 and < 80 years of age; 3. diagnosed as POAG according to the diagnostic criteria of POAG used in current ophthalmology practice; 4. not legally blind by the official definition of having central visual acuity of 20/200 or less in the better eye with corrective lenses, and /or a visual field of 20 degrees or less in the better eye; 5. never before treated with deep acupuncture at acupoint Jingming BL1 for glaucoma.；
请登录查看Exclusion criteria will be as follows: 1. Participants with cardiovascular, kidney, liver, or hematopoietic system diseases, mental health disorders, cancer or other severe diseases for whom acupuncture may be inappropriate or unsafe; 2. Participants with other diseases that could interfere with acupuncture treatment, e.g., clotting disorders or leukopenia, active skin infection, epilepsy, or on anticoagulant therapy (aspirin, warfarin etc); 3. Participants with a pacemaker, metal allergy, or severe fear of needles; 4. Women who are pregnant or lactating; 5. Participants who have difficulties in attending the trial (e.g. paralysis, cancer, dementia, drug addiction, time constraints, surgical operation).；
请登录查看马来西亚雅兰大学
43000
马来西亚雅兰大学的其他临床试验
马来西亚雅兰大学的其他临床试验
最新临床资讯
-
一项5年临床安全随访研究启示：#脐带间充质干细胞（#hUC-MSCs）
SCLnow圣释2026-11-11
-
SYNCHRONIZE-CVOT试验达到主要终点，索弗度肽（survodutide）成为全球首个证实心血管安全性的胰高血糖素/GLP-1双受体激动剂
勃林格殷格翰中国2026-11-11
-
医药观澜2026-11-11
-
宜明昂科2026-11-11
-
医学科学院精准医学研究所2026-11-11
-
多肽圈2026-11-11
-
多肽圈2026-11-11
-
求是网2026-11-11
-
干细胞之父2026-11-11
-
和田维药2026-11-11
全球药物研发中心
全球研发数据与行业前沿情报
研发动态
相关报告
政策法规
-
2026-11-12
-
2026-11-12
-
2026-11-12
-
摩熵咨询 20 3
-
摩熵咨询 33 62
-
摩熵咨询 20 3
-
颁布机构：国家卫生健康委办公厅、 2026-11-10
-
颁布机构：国家卫健委（原国家卫计委） 2026-11-10
-
颁布机构：国家药品审评中心（CDE） 2026-10-16
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
市场动态
市场报告
政策法规
-
2026-11-11
-
2026-11-11
-
2026-11-11
-
摩熵咨询 35 92
-
摩熵咨询 28 74
-
摩熵咨询 34 49
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-04